ESPR Q2 2018 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

-$40M

Operating Income

-$46M

Net Income

-$46M

EPS (Diluted)

$-1.71

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$211M

Total Liabilities

$35M

Stockholders' Equity

$176M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$40M	$0	—
Operating Income	-$46M	-$44M	-6.5%
Net Income	-$46M	-$43M	-5.5%